Emerging Treatments for Classical Myeloproliferative Neoplasms

The authors illustrate the current landscape of novel therapies that are under evaluation for patients with myeloproliferative neoplasms on the basis of current guidelines, patient risk stratification criteria, and previous experience.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.